Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- Product Overview:
Cytosolic ?-glucosidase (GBA3) is a neutral ?-glucocerebrosidase.{60901,60902} It is composed of a single glycoside hydrolase domain and hydrolyzes glucosyl- and galactosylceramides. GBA3 is expressed in the liver, small intestine, colon, spleen, and kidneys.{60904} In vitro, knockdown of GBA3 inhibits mitotic arrest and promotes resistance to paclitaxel (Item No. 10461) in colon cancer cells.{60905} Tumor levels of GBA3 are lower in patients with hepatocellular carcinoma and decreased expression is associated with poor prognosis.{60906} Unlike GBA1, polymorphisms in GBA3 are not associated with Gaucher disease, a lysosomal storage disorder.{60953} Cayman’s GBA3 (human, recombinant) protein can be used for enzyme activity assays. This protein consists of 480 amino acids and has a calculated molecular weight of 55 kDa.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.